BIIB

insider transactions

BIOGEN INC. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 9, 26

William A Hawkins

Director

$0

1.5K sh

Own +17%
Grant·A
Jun 9, 26

SHERWIN STEPHEN A

Director

$0

1.5K sh

Own +11%
Grant·A
Jun 9, 26

Eric K Rowinsky

Director

$0

1.5K sh

Own +6%
Grant·A
Jun 9, 26

Jesus B Mantas

Director

$0

1.5K sh

Own +15%
Grant·A
Jun 9, 26

Susan Langer

Director

$0

1.5K sh

Own +29%
Grant·A
Jun 9, 26

Monish D Patolawala

Director

$0

1.5K sh

Own +41%
Exercise·M
Jun 9, 26

Menelas N Pangalos

Director

$0

2.4K sh

Own New
Grant·A
Jun 9, 26

Menelas N Pangalos

Director

$0

1.5K sh

Own +64%
Exercise·M
Jun 9, 26

Menelas N Pangalos

Director

$0

2.4K sh

Own New
Grant·A
Jun 9, 26

Lloyd Minor

Director

$0

1.5K sh

Own +64%
Grant·A
Jun 9, 26

Maria C Freire

Director

$0

2.0K sh

Own +29%
Exercise·M
May 1, 26

Adam Keeney

Head of Corporate Development

$0

939 sh

Own New
Other·F
May 1, 26

Adam Keeney

Head of Corporate Development

$85.1K

455 sh · $187.06

Own -7%
Exercise·M
May 1, 26

Adam Keeney

Head of Corporate Development

$0

939 sh

Own +16%
Exercise·M
Apr 1, 26

Sean Godbout

Chief Accounting Officer

$0

181 sh

Own +99%
Other·F
Apr 1, 26

Sean Godbout

Chief Accounting Officer

$9.9K

54 sh · $183.78

Own -4%
Exercise·M
Apr 1, 26

Sean Godbout

Chief Accounting Officer

$0

181 sh

Own +15%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 9, 2026	William A Hawkins	Director	Grant A	1.5K	+17%	—	$0
Jun 9, 2026	SHERWIN STEPHEN A	Director	Grant A	1.5K	+11%	—	$0
Jun 9, 2026	Eric K Rowinsky	Director	Grant A	1.5K	+6%	—	$0
Jun 9, 2026	Jesus B Mantas	Director	Grant A	1.5K	+15%	—	$0
Jun 9, 2026	Susan Langer	Director	Grant A	1.5K	+29%	—	$0
Jun 9, 2026	Monish D Patolawala	Director	Grant A	1.5K	+41%	—	$0
Jun 9, 2026	Menelas N Pangalos	Director	Exercise M	2.4K	New	—	$0
Jun 9, 2026	Menelas N Pangalos	Director	Grant A	1.5K	+64%	—	$0
Jun 9, 2026	Menelas N Pangalos	Director	Exercise M	2.4K	New	—	$0
Jun 9, 2026	Lloyd Minor	Director	Grant A	1.5K	+64%	—	$0
Jun 9, 2026	Maria C Freire	Director	Grant A	2.0K	+29%	—	$0
May 1, 2026	Adam Keeney	Head of Corporate Development	Exercise M	939	New	—	$0
May 1, 2026	Adam Keeney	Head of Corporate Development	Other F	455	-7%	$187.06	$85.1K
May 1, 2026	Adam Keeney	Head of Corporate Development	Exercise M	939	+16%	—	$0
Apr 1, 2026	Sean Godbout	Chief Accounting Officer	Exercise M	181	+99%	—	$0
Apr 1, 2026	Sean Godbout	Chief Accounting Officer	Other F	54	-4%	$183.78	$9.9K
Apr 1, 2026	Sean Godbout	Chief Accounting Officer	Exercise M	181	+15%	—	$0

About BIIB insider trading

This page tracks insider transactions for BIOGEN INC. (BIIB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.